Prevalence of HPV infection among females in the United States
Prevalence of HPV infection among females in the United States
复制标题
DOI：
10.1001/jama.297.8.813
复制
发表时间：
2007-02-28
影响因子：
120.7
通讯作者：
Markowitz, Lauri E.
中科院分区：
文献类型：
--
作者：
Dunne, Eileen F.;Unger, Elizabeth R.;Markowitz, Lauri E.
人类乳头瘤病毒（HPV）感染是最常见的性传播感染。HPV感染在美国的预防性HPV疫苗的广泛使用之前的基线人口患病率数据将是useful.Objective要确定HPV的患病率之间的女性在UnitedStates.Design，设置，和参与者的国家健康和营养检查调查（NHANES）使用的美国noninstitutionalized平民人口的代表性样本。在移动的检查中心对2003-2004年国家健康和营养状况调查中在家中接受访谈的14至59岁女性进行检查，并提供自我采集的阴道拭子样本。通过L1共有聚合酶链反应，然后进行型特异性杂交，分析拭子中的HPV DNA。人口统计学和性行为的信息，从所有participator.Main结果测量HPV患病率通过polymerase chain reaction.Results的总体HPV患病率为26.8%（95%置信区间[CI]，23.3%-30.9%）之间的美国女性年龄在14至59岁（n= 1921）。HPV感染率为24.5%（95% CI，19.6%-30.5%）14 - 19岁女性中，44.8%（95% CI，36.3%-55.3%），20至24岁女性中，27.4%（95% CI，21.9%-34.2%）25 - 29岁女性中，27.5%（95% CI，20.8%-36.4%）30 - 39岁女性中，25.2%（95% CI，19.7%-32.2%），50 - 59岁女性为19.6%（95% CI，14.3%-26.8%）。14 ~ 24岁年龄组HPV感染率随年龄增长而增高，差异有统计学意义（P
Context Human papillomavirus (HPV) infection is estimated to be the most common sexually transmitted infection. Baseline population prevalence data for HPV infection in the United States before widespread availability of a prophylactic HPV vaccine would be useful.Objective To determine the prevalence of HPV among females in the United States.Design, Setting, and Participants The National Health and Nutrition Examination Survey ( NHANES) uses a representative sample of the US noninstitutionalized civilian population. Females aged 14 to 59 years who were interviewed at home for NHANES 2003-2004 were examined in a mobile examination center and provided a self-collected vaginal swab specimen. Swabs were analyzed for HPV DNA by L1 consensus polymerase chain reaction followed by type-specific hybridization. Demographic and sexual behavior information was obtained from all participants.Main Outcome Measures HPV prevalence by polymerase chain reaction.Results The overall HPV prevalence was 26.8% (95% confidence interval [CI], 23.3%-30.9%) among US females aged 14 to 59 years (n= 1921). HPV prevalence was 24.5% ( 95% CI, 19.6%-30.5%) among females aged 14 to 19 years, 44.8% ( 95% CI, 36.3%-55.3%) among women aged 20 to 24 years, 27.4% ( 95% CI, 21.9%-34.2%) among women aged 25 to 29 years, 27.5% ( 95% CI, 20.8%-36.4%) among women aged 30 to 39 years, 25.2% ( 95% CI, 19.7%-32.2%) among women aged 40 to 49 years, and 19.6% (95% CI, 14.3%-26.8%) among women aged 50 to 59 years. There was a statistically significant trend for increasing HPV prevalence with each year of age from 14 to 24 years ( P